Company appears to be very bullish and confident ahead of the FDA’s upcoming mid-cycle review of Botanix’s application for its lead product, Sofpironium Bromide.
1. The latest headlines on Botanix News Hub
2. This morning, Company's Tweeter Account has posted last week's article on The West Australia about the FDA’s upcoming mid-cycle review of Botanix’s application for its lead product, Sofpironium Bromide, after a Trading Halt and the Press Article Correction, to create more publicity or to assure we are on the winning team?
Ann: Press Article Correction, page-103
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.0¢ |
Change
-0.010(2.94%) |
Mkt cap ! $615.4M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.0¢ | 33.0¢ | $312.1K | 926.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 211578 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 54719 | 2 |
View Market Depth
| Last trade - 10.19am 07/08/2024 (20 minute delay) ? |
| BOT (ASX) Chart |